Crossmark

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Published Online: 2014-10-13

Published Print: 2015-02

Authors

Suzuki, R

Hideshima, T

Mimura, N

Minami, J

Ohguchi, H

Kikuchi, S

Yoshida, Y

Gorgun, G

Cirstea, D

Cottini, F

Jakubikova, J

Tai, Y-T

Chauhan, D

Richardson, P G

Munshi, N C

Utsugi, T

Anderson, K C
License Information

Text and Data Mining valid from 2014-10-13

Version of Record valid from 2014-10-13
More Information

Article History

First Online: 13 October 2014

Competing interests

: TU is an employee at Taiho Pharmaceutical Co., Ltd. Y-TT is a consultant for Onyx. DC is a consultant for Oncopeptides AB. PGR is a member of advisory board for Celgene, Millennium, Johnson and Johnson, Novartis and Bristol–Myers Squibb. NM is a member of advisory board for Millennium, Celgene and Novartis. TH is a consultant for Acetylon Pharmaceuticals. KCA is a member of advisory board for Onyx, Celgene, Gilead and Sanofi-Aventis, and is a scientific founder of Acetylon and Oncopep. Other authors declare no conflict of interest.

Document is current